Communiqués Provectus Biopharmaceuticals, Inc.

Actions

PVCT

US74373P1084

Recherche biotechnologique et médicale

Temps Différé OTC Markets 16:05:45 27/08/2026			Varia. 5j.	Varia. 1 janv.
0,0598 ^USD	+1,56 %		+8,80 %	+7,16 %

13/08	Provectus Biopharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
07/07	Provectus Biopharmaceuticals, Inc. met en avant une étude évaluée par les pairs démontrant les effets mécanistes opposés du Rose Bengale sodique à une dose identique	CI

Communiqués

13/08	Provectus: Q2 Earnings Snapshot	AQ
22/07	VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase	AQ
07/07	Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose	AQ
30/06	Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections	AQ
25/06	Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)	AQ
08/06	Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders	AQ
18/05	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End	AQ
14/05	Provectus: Q1 Earnings Snapshot	AQ
04/05	Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis	AQ
21/04	Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee	AQ
02/04	Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment	AQ
26/03	Provectus: Q4 Earnings Snapshot	AQ
13/11	Provectus: Q3 Earnings Snapshot	AQ
10/10/25	Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants, University of Calgary Research Highlights Novel STING-Pathway Activation	AQ
09/10/25	Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy	AQ
29/09/25	Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer	AQ
14/08/25	Provectus: Q2 Earnings Snapshot	AQ
26/06/25	Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer	AQ
09/06/25	Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders	AQ
15/05/25	Provectus: Q1 Earnings Snapshot	AQ
15/01/25	Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs	AQ
14/01/25	Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs	AQ
12/12/24	Provectus Biopharmaceuticals Launches VisiRose, Provectus s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology	AQ
11/12/24	Provectus Biopharmaceuticals - VisiRose Introduces Revolutionary Therapy for Severe Eye Infections	AQ
11/12/24	Provectus Biopharmaceuticals : VisiRose Introduces Revolutionary Therapy for Severe Eye Infections Form 8 K	PU